Amgen Inc (NASDAQ:AMGN) has experienced a roller-coaster in the market with fluctuating stock values. The shares saw a dip due to some questions regarding released clinical data. Cardinal Capital Management Inc., Auxier Asset Management, and Garde Capital Inc. were among firms that lowered their stakes, leading to more discussion about stock performance. There was growing intrigue in the obesity injection that Amgen is pioneering; this has driven significant interest from investors, with the stock seeing gains after teasing data of its weight-loss drug. The pharmaceutical giant's Q1 earnings also topped expectations, thanks to an update on obesity drug development. Amgen's experimental obesity drug has the stock soaring. The company is also to submit a Teprotumumab marketing authorization application to the European Union. The FDA has approved its Uplizna - a drug for rare disease, and its Tarlatamab for Small Cell Lung Cancer. Amgen has been lauded for outperforming the industry and is showing positive signs with its new biomufacturing site in Central Ohio. Currently, the company is drawing investors for its promising weight-loss drug.
Amgen AMGN News Analytics from Thu, 09 Nov 2023 06:15:22 GMT to Sun, 16 Jun 2024 17:31:03 GMT -
Rating 3
- Innovation 3
- Information 5
- Rumor 1
